Jeffrey M. Sundstrom, M.D.,Ph.D.

Jeffrey M. Sundstrom, M.D.,Ph.D.
Penn State Hershey Eye Center
100 Campus Drive, Entrance 1, Suite 800
Hershey, PA 17033
Publications:
View My Publications
4.7 out of 5
140 Patient Satisfaction Ratings
  • Ophthalmology

Board Certified, American Board of Ophthalmology

RESEARCH INTERESTS

Dr. Sundstrom’s research program focuses on the development of biomarkers and novel therapeutic targets for age-related macular degeneration (AMD), the leading cause of legal blindness in the United States.  In 2006, intravitreal injection of anti-VEGF antibodies were shown to improve vision in patients with neovascular AMD.  Although this intervention has revolutionized the treatment of AMD, less than half of the patients respond with modest improvements visual acuity and no treatment exists for non-exudative AMD.  Dr. Sundstrom has developed a deep proteomics assay capable of identifying retinal derived proteins from clinical vitreous samples.    Comparative vitreous proteomic studies are ongoing in an effort to identify proteins associated with end-stage neovascular and non-exudative AMD.  Preclinical research will subsequently be conducted to validate these newly identified biomarkers and/or therapeutic targets.  Dr. Sundstrom’s educational responsibilities include mentoring medical students for the Medical Student Research project as well as teaching Ophthalmology residents both in the clinic and through a monthly Retina Imaging Conference.

Fellowship, Medical Retina
University of Michigan Medical School (Ann Arbor) - 2013

Residency, Ophthalmology
Milton S. Hershey Medical Center - 2012

Internship, Medicine
Milton S. Hershey Medical Center - 2009

M.D.,
Penn State Hershey College of Medicine - 2008

  • Bennet and Inez Chotiner Early Career Assistant Professor of Ophthalmology, Neural and Behavioral Sciences, and Cellular & Molecular Physiology
  • Diabetic Retinopathy
  • Eye care
  • Medical Retina
  • American Ophthalmological Society Travel Grant, 2013
  • Heed Fellowship, 2012
  • Development of biomarkers and novel therapeutic targets for age-related macular degeneration (AMD), the leading cause of legal blindness in the United States.

My Practice Locations

My Practice Locations